2m 2m 2m 2m 2m 2m 2m
LYELL IMMUNPHRM (LYEL)
NASDAQ
$12.63-$2.26 (-15.18%)
Price as of Jun 03, 2026 7:47 PM EDT- $404.4MMarket Cap
- 86.36%1-Year Change
- BiotechnologyIndustry
LYELL IMMUNPHRM (LYEL)
$12.63-$2.26 (-15.18%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 36,000 -40.98% | 61,000 -53.08% | 130,000 -99.85% | 84.7M +695.15% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 36,000 -40.98% | 61,000 -53.08% | 130,000 -99.85% | 84.7M +695.15% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -158.7M -7.53% | -171.6M -6.20% | -182.9M +14.92% | -159.2M +14.78% | |
Depreciation and Amortization Expense | 11.5M -41.22% | 19.6M -3.06% | 20.3M +12.38% | 18.0M +32.27% | |
Total Operating Expenses | 269.4M -24.91% | 358.8M +45.19% | 247.1M -9.05% | 271.7M +20.55% | |
Operating Profit | -269.4M -24.91% | -358.8M +45.24% | -247.0M +32.05% | -187.1M -12.91% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -5.0M -132.00% | 15.8M +27.35% | 12.4M +214.11% | 3.9M +111.12% | |
Income before Taxes | -269.4M -24.91% | -358.8M +45.24% | -247.0M +34.89% | -183.1M -26.82% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -274.4M -19.98% | -343.0M +46.18% | -234.6M +28.13% | -183.1M -26.82% | |
Net Income from Continuing Operations Applicable to Common | -274.4M -19.98% | -343.0M +46.18% | -234.6M +28.13% | -183.1M -26.82% | |
Basic EPS and Net Income | -16.06 +1,125.95% | -1.31 +40.86% | -0.93 +25.68% | -0.74 -59.78% | |
Diluted EPS and Net Income | -16.06 +1,125.95% | -1.31 +40.86% | -0.93 +25.68% | -0.74 -59.78% | |
Basic Weighted Average Shares | 17.1M -93.46% | 261.5M +4.18% | 251.0M +1.58% | 247.1M +181,686.08% | |
Diluted Weighted Average Shares | 17.1M -93.46% | 261.5M +4.18% | 251.0M +1.58% | 247.1M +181,686.08% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 60.2M -43.01% | 105.6M -27.50% | 145.6M +17.88% | 123.6M -57.95% | |
Short-Term Investments | 187.0M -29.40% | 264.9M -33.86% | 400.6M -22.46% | 516.6M +60.95% | |
Cash and Cash Equivalents and Short-Term Investments | 247.2M -33.28% | 370.5M -32.17% | 546.2M -14.67% | 640.2M +4.12% | |
Total Current Assets | 260.9M -31.26% | 379.6M -31.57% | 554.7M -14.83% | 651.3M +3.99% | |
Accumulated Depreciation | 74.3M +5.09% | 70.7M +36.85% | 51.6M +59.48% | 32.4M +123.14% | |
Property and Plant and Equipment and Net | 34.8M -27.86% | 48.2M -53.05% | 102.7M -16.56% | 123.0M +2.44% | |
Total Long-Term Assets | 4.9M +5.71% | 4.6M +9.14% | 4.2M -9.51% | 4.7M +34.37% | |
Total Assets | 340.1M -30.72% | 490.9M -34.55% | 750.0M -20.00% | 937.6M -16.84% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Total Current Liabilities | 49.4M -8.14% | 53.8M +55.82% | 34.5M -6.78% | 37.0M -20.78% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Total Long-Term Liabilities | 517,000 -84.11% | 3.3M -11.22% | 3.7M -10.92% | 4.1M -9.92% | |
Total Liabilities | 91.8M -14.98% | 108.0M +13.63% | 95.1M -8.85% | 104.3M -47.22% | |
Retained Earnings | -1.6B +20.40% | -1.3B +34.23% | -1.0B +30.57% | -767.5M +31.34% | |
Total Stockholders Equity | 248.2M -35.17% | 382.8M -41.55% | 655.0M -21.40% | 833.3M -10.38% | |
Total Shares Outstanding | 21.3M -92.79% | 294.9M +16.11% | 254.0M +1.76% | 249.6M +2.81% | |
Cash Flow | |||||
Cash from Operating Activities | -150.0M -7.62% | -162.4M -0.79% | -163.7M -3.46% | -169.6M +34.30% | |
Capital Expenditures | 780,000 +68.10% | 464,000 -82.73% | 2.7M -88.94% | 24.3M -62.94% | |
Cash from Investing Activities | 54.1M -55.81% | 122.4M -33.48% | 184.0M +1,694.87% | -11.5M -90.51% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 50.4M +3,701.36% | 1.3M -23.92% | 1.7M -83.61% | 10.6M -97.35% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -748,344.44% +27.24% | -588,122.95% +209.53% | -190,006.15% +85,917.67% | -220.89% N/A | |
Return on Assets | -66.06% +19.50% | -55.28% +98.81% | -27.81% +56.78% | -17.74% N/A | |
Return on Equity | -86.98% +31.59% | -66.10% +109.63% | -31.53% +51.79% | -20.77% N/A | |
Revenue Growth | -40.98% -22.78% | -53.08% -46.84% | -99.85% -114.36% | 695.15% N/A | |
Current Ratio | 5.28 -25.17% | 7.06 -56.08% | 16.07 -8.64% | 17.59 N/A | |
Cash Ratio | 1.22 -37.96% | 1.96 -53.47% | 4.22 +26.45% | 3.34 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 0.00 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 0.00 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow